Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients With Chronic Myocardial Ischemia

BackgroundCatheter-based myocardial gene transfer (GTx) has not been previously tested in human subjects. Accordingly, we performed a pilot study to investigate the feasibility and safety of catheter-based myocardial GTx of naked plasmid DNA encoding vascular endothelial growth factor-2 (phVEGF-2) in patients with chronic myocardial ischemia. Methods and ResultsA steerable, deflectable 8F catheter incorporating a 27-guage needle was advanced percutaneously to the left ventricular myocardium of 6 patients with chronic myocardial ischemia. Patients were randomized (1:1) to receive phVEGF-2 (total dose, 200 &mgr;g), which was administered as 6 injections into ischemic myocardium (total, 6.0 mL), or placebo (mock procedure). Injections were guided by NOGA left ventricular electromechanical mapping. Patients initially randomized to placebo became eligible for phVEGF-2 GTx if they had no clinical improvement 90 days after their initial procedure. Catheter injections (n=36) caused no changes in heart rate or blood pressure. No sustained ventricular arrhythmias, ECG evidence of infarction, or ventricular perforations were observed. phVEGF-2–transfected patients experienced reduced angina (before versus after GTx, 36.2±2.3 versus 3.5±1.2 episodes/week) and reduced nitroglycerin consumption (33.8±2.3 versus 4.1±1.5 tablets/week) for up to 360 days after GTx; reduced ischemia by electromechanical mapping (mean area of ischemia, 10.2±3.5 versus 2.8±1.6 cm2, P =0.04); and improved myocardial perfusion by SPECT-sestamibi scanning for up to 90 days after GTx when compared with images obtained after control procedure. ConclusionsThis randomized trial of catheter-based phVEGF-2 myocardial GTx provides preliminary indications regarding the feasibility, safety, and potential efficacy of percutaneous myocardial GTx to human left ventricular myocardium.

[1]  R. Hendel,et al.  Short- and Intermediate-Term Clinical Outcomes From Direct Myocardial Laser Revascularization Guided by Biosense Left Ventricular Electromechanical Mapping , 2000, Circulation.

[2]  J. Isner,et al.  Left Ventricular Electromechanical Mapping to Assess Efficacy of phVEGF165 Gene Transfer for Therapeutic Angiogenesis in Chronic Myocardial Ischemia , 2000, Circulation.

[3]  K. Endresen,et al.  Transmyocardial Revascularization Transmyocardial Revascularization With CO 2 Laser in Patients With Refractory Angina Pectoris Clinical Results from The Norwegian Randomized Trial , 2016 .

[4]  Y. Vodovotz,et al.  Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models. , 2000, Journal of the American College of Cardiology.

[5]  J. Isner,et al.  Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. , 1999, Human gene therapy.

[6]  O. Frazier,et al.  Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. , 1999, The New England journal of medicine.

[7]  Robert D. Dowling,et al.  Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. , 1999, The New England journal of medicine.

[8]  J. Isner,et al.  Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. , 1999, The Annals of thoracic surgery.

[9]  J. Isner,et al.  Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. , 1999, Journal of the American College of Cardiology.

[10]  J. Isner,et al.  Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. , 1998, Journal of vascular surgery.

[11]  L Gepstein,et al.  Electromechanical characterization of chronic myocardial infarction in the canine coronary occlusion model. , 1998, Circulation.

[12]  M. Leon,et al.  Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. , 1998, Circulation.

[13]  K Walsh,et al.  Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. , 1998, Circulation.

[14]  D. Berman,et al.  Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. , 1997, Journal of the American College of Cardiology.

[15]  L. Gepstein,et al.  A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart. In vitro and in vivo accuracy results. , 1997, Circulation.

[16]  J. Isner,et al.  Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. , 1996, Circulation.

[17]  Mark E. Josephson,et al.  Nonfluoroscopic, in vivo navigation and mapping technology , 1996, Nature Medicine.

[18]  Peipei Ping,et al.  Intracoronary gene transfer of fibroblast growth factor–5 increases blood flow and contractile function in an ischemic region of the heart , 1996, Nature Medicine.

[19]  J. Isner,et al.  Constitutive Expression of phVEGF 165 After Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients With Critical Limb Ischemia Clinical Investigation and Reports , 1998 .